Clinical Trial Results:
A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) in comparison to Metvix® in the treatment of non-aggressive basal cell carcinoma (BCC) with photodynamic therapy (PDT)
Summary
|
|
EudraCT number |
2013-003241-42 |
Trial protocol |
DE GB |
Global end of trial date |
17 Nov 2015
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
25 Nov 2017
|
First version publication date |
01 Dec 2016
|
Other versions |
v1 |
Version creation reason |
|
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
ALA-BCC-CT008
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Biofrontera Bioscience GmbH
|
||
Sponsor organisation address |
Hemmelrather Weg 201, Leverkusen, Germany, 51377
|
||
Public contact |
Clinical Trial Department, Biofrontera Bioscience GmbH, +49 2148763210, ameluz@biofrontera.com
|
||
Scientific contact |
Clinical Trial Department, Biofrontera Bioscience GmbH, +49 2148763210, ameluz@biofrontera.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
17 Nov 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
17 Nov 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
17 Nov 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of the study is to compare the efficacy of BF-200 ALA containing 7.8% 5-aminolevulinic acid (ALA) as active ingredient with the comparator Metvix®, containing 16% methyl-aminolevulinate in the treatment of thin, non-aggressive BCC with photodynamic therapy.
|
||
Protection of trial subjects |
Subject protection was ensured by following high medical and ethical standards in accordance with the principles laid down in the Declaration of Helsinki, and that are consistent with Good Clinical Practice and applicable regulations.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
28 Jan 2014
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety, Efficacy | ||
Long term follow-up duration |
5 Years | ||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 42
|
||
Country: Number of subjects enrolled |
Germany: 352
|
||
Worldwide total number of subjects |
394
|
||
EEA total number of subjects |
394
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
139
|
||
From 65 to 84 years |
245
|
||
85 years and over |
10
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
Trial was conducted in Germany and Great Britain with a total of 24 sites who recruited patients. Enrollment of patients started (first patient enrolled) 28-Jan-2014. | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
Of the 394 patients enrolled in this study, 281 patients were randomized (138 patients to BF-200 ALA and 143 patients to Metvix®). 113 patients enrolled were excluded before randomization due to screening failure (104 patients), patient’s decision (7 patients), and lost to FU and “other reason” (each 1 patient). All randomized patients treated. | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
clinical phase/ observer-blind period (overall period)
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Single blind | |||||||||||||||||||||
Roles blinded |
Investigator [1] | |||||||||||||||||||||
Blinding implementation details |
Study medication randomized 1:1. IMPs have different consitencies. To guarantee the observer-blind status of the investigator assessing efficacy after each PDT session, a 2nd investigator/delegated person performed IMP application, illumination and conducted all safety evaluations during illumination period. Randomization schedule and allocation to treatment groups were not known to the investigator & sponsor until completion of study, except in case of emergency.
|
|||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Metvix® | |||||||||||||||||||||
Arm description |
containing 16% methyl-aminolevulinate (MAL) | |||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||
Investigational medicinal product name |
Metvix®
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||||||||
Routes of administration |
Topical use
|
|||||||||||||||||||||
Dosage and administration details |
The dose for Metvix® was up to 1 g per PDT session (depending on size and number of target lesions located on neck, trunk, extremities, face or scalp, no more than 2 illumination areas with a maximum area including margin of 10 cm², and a film thickness of about 1 mm). Up to 4 administrations of study treatment, which included PDT sessions (PDT-1, PDT-2, PDT-3, and PDT-4) were applied. For all patients, PDT-1 was to be administered directly after randomization and PDT-2 was to be administered approximately 1 week later. The total number of PDT sessions per patient depended on response as follows: Complete responders (lesions totally cleared clinically) 12 weeks after PDT-2: entered the FU part of the study with no further treatment. Partial or non-responders 12 weeks after PDT-2 were retreated with the same study treatment by applying 2 additional PDTs in a second PDT cycle and then entered FU.
|
|||||||||||||||||||||
Arm title
|
BF-200 ALA | |||||||||||||||||||||
Arm description |
BF-200 ALA (also referred to as Ameluz®) containing 7.8% 5-aminolevulinic acid (5-ALA) | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
BF-200 ALA
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
Ameluz
|
|||||||||||||||||||||
Pharmaceutical forms |
Gel
|
|||||||||||||||||||||
Routes of administration |
Topical use
|
|||||||||||||||||||||
Dosage and administration details |
The dose for BF-200 ALA was up to 1 g per PDT session (depending on size and number of target lesions located on neck, trunk, extremities, face or scalp, no more than 2 illumination areas with a maximum area including margin of 10 cm², and a film thickness of about 1 mm). Up to 4 administrations of study treatment, which included PDT sessions (PDT-1, PDT-2, PDT-3, and PDT-4) were applied. For all patients, PDT-1 was to be administered directly after randomization and PDT-2 was to be administered approximately 1 week later. The total number of PDT sessions per patient depended on response as follows: Complete responders (lesions totally cleared clinically) 12 weeks after PDT-2: entered the FU part of the study with no further treatment. Partial or non-responders 12 weeks after PDT-2 were retreated with the same study treatment by applying 2 additional PDTs in a second PDT cycle and then entered FU.
|
|||||||||||||||||||||
Notes [1] - The roles blinded appear inconsistent with a simple blinded trial. Justification: During this study, the investigator assessing efficay after each PDT session was observer-blind. A second investigator or delegated person performed drug application, light treatment, and safety evaluation during illumination period. This was important since IMPs can be distinguised by their texture and consistency. IMPs have a comparable safety profile. |
||||||||||||||||||||||
|
||||||||||||||||||||||
Notes [2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: 394 subjects enrolled. 113 not randomized, 281 randomized (143 received Metvix, 138 received BF-200-ALA). Due to non-randomized subjects, the number of enrolled subjects is not equal to the number of subjects in the clinical phase. 11 patients (Metvix) & 10 patients (BF-200-ALA) did not complete the study. Note that 1 dropout per group to be accounted for an AE in follow up (due to AE recording until DBL). It was not possible to enter "10" for Metvix and "9" for BF-200-ALA for "not completed". |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Metvix®
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
containing 16% methyl-aminolevulinate (MAL) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
BF-200 ALA
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
BF-200 ALA (also referred to as Ameluz®) containing 7.8% 5-aminolevulinic acid (5-ALA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Metvix®
|
||
Reporting group description |
containing 16% methyl-aminolevulinate (MAL) | ||
Reporting group title |
BF-200 ALA
|
||
Reporting group description |
BF-200 ALA (also referred to as Ameluz®) containing 7.8% 5-aminolevulinic acid (5-ALA) |
|
|||||||||||||
End point title |
overall patient complete response assessed 12 weeks after the last PDT | ||||||||||||
End point description |
overall patient complete response assessed 12 weeks after the last PDT.
The indicated values give precentage of overall complete responders. An overall complete responder is defined as a patient in whom all treated lesions were cleared. The PP set is the primary analysis set for the analyses of the primary endpoint.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
12 weeks after the last PDT.
Please note: 2 PDT-cycles, each cycle consisting of 2 PDTs (=maximum of 4 PDTs per patient) was possible.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Difference in % points to BF-200 ALA | ||||||||||||
Comparison groups |
Metvix® v BF-200 ALA
|
||||||||||||
Number of subjects included in analysis |
231
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Farrington and Manning (non-inferiority) | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
1.6
|
||||||||||||
Confidence interval |
|||||||||||||
level |
97.5% | ||||||||||||
sides |
1-sided
|
||||||||||||
lower limit |
-6.5 | ||||||||||||
upper limit |
- |
|
|||||||||||||
End point title |
Lesion complete response assessed 12 weeks after the last PDT | ||||||||||||
End point description |
Lesion complete response (completely cleared individual lesions) assessed 12 weeks after the last PDT.
The indicated values give precentage of overall completly cleared individual lesions. The PP set is the primary analysis set for the analyses of the secondary endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
12 weeks after the last PDT.
Please note: 2 PDT-cycles, each cycle consisting of 2 PDTs (=maximum of 4 PDTs per patient) was possible.
|
||||||||||||
|
|||||||||||||
Notes [1] - this is the number of patients that received Metvix. They had 127 lesions in total. [2] - This is the number of patients that received BF-200 ALA. They had 148 lesions in total. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Reduction of total lesion area 12 weeks after last PDT compared to baseline | ||||||||||||
End point description |
Reduction of total lesion area (summation of sizes of all treated lesions) per patient, assessed 12 weeks after the last PDT. The PP set is the primary analysis set for the analyses of the secondary endpoint.
Please note that the high SD for BF-200 ALA is due to a patient who had increased lesion area from 63 square-mm at baseline to 225 square-mm 12 weeks after PDT. This lesion area included a lesion that was later confirmed to be benign skin condition (lentigo solaris).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
12 weeks after the last PDT.
Please note: 2 PDT-cycles, each cycle consisting of 2 PDTs (=maximum of 4 PDTs per patient) was possible.
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||
End point title |
Cosmetic outcome 12 weeks after last PDT (sum score at baseline of 0 to 3) | |||||||||||||||||||||||||||
End point description |
The PP set is the primary analysis set for the analyses of the secondary endpoint.
|
|||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
12 weeks after the last PDT.
Please note: 2 PDT-cycles, each cycle consisting of 2 PDTs (=maximum of 4 PDTs per patient) was possible.
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||
End point title |
Cosmetic oucome 12 weeks after last PDT (sum score at baseline of 1 to 3, 0 excluded) | |||||||||||||||||||||||||||
End point description |
||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
12 weeks after the last PDT.
Please note: 2 PDT-cycles, each cycle consisting of 2 PDTs (=maximum of 4 PDTs per patient) was possible.
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Patient complete response, 12 weeks after PDT-2 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
12 weeks after PDT-2.
Please note, 2 PDT-cycles, each consisting of 2 PDTs (=maximum of PDTs per patient) was possible.
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
28-Jan-2014 (first patient's informed consent) until date of DBL (data base lock, 22-Jan-2016)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
BF-200 ALA
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Metvix
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
14 Nov 2014 |
This amendment, which affected all study sites, was dated 14 November 2014, after a total of 181 patients had been enrolled and treated. Changes and clarifications to inclusion and exclusion criteria were amended to be able to enhance patient enrollment. This change was implemented to improve recruitment. Patients enrolled after this change were expected to be comparable from a medicinal point of view
and no differences in efficacy and tolerability were to be expected in comparison to those patients who had already been included in the study. This assumption was based on the fact that the applied treatment is topical and locally restricted. Thus the change in the in-/exclusion criteria was not expected to influence the composition of the enrolled population. |
||
07 May 2015 |
This amendment, which affected all study sites, was dated 07 May 2015 (for Protocol version 4 for Germany and the 18 May 2015 for Protocol version 4.1 in the UK), after a total of 274 or 275 patients respectively had been enrolled and treated.
This amendment reduced the sample size from a total of 360 patients to a total of 272 patients because a higher overall response than originally anticipated was observed during the blinded monitoring of the study. In addition, the requirement that “all the pages of the patient information had to be initialed and dated by the patient to confirm the comprehension” was deleted because signing and dating of the last page of the ICF is sufficient according to European regulations. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |